¡¡ Home CAS Center for Excellence


Members of CAS, CAE
National Outstanding Young Scientists Award
Principal Investigators
Address: 320 Yue Yang Road, Shanghai 200031, P.R. China
Tel: 86-21-54920000
Fax: 86-21-54921011
Email: sibcb@sibs.ac.cn
Website: www.sibcb.ac.cn
Principal Investigators
JI Hongbin
Ph.D., Professor
Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-yang Road, Shanghai 200031, China.
Email: hbji@@sibcb.ac.cn

Research Areas
lung cancer; metastasis; biomarkers; genomics; genetics; metabolism;oncogenes; tumor suppressors; mouse model; drug discovery; LKB1; EGF receptor kinase domain mutation;

Research Interests
Lung cancer is one of the most devastating diseases worldwide with 5-year survival rate approximately 15%. The high mortality is mainly attributable to the poor understanding of the mechanisms involved in lung cancerigenesis. Our research interest is to decipher the molecular mechanisms involved in lung cancer initiation, malignant progression, transdifferentiation and metastasis, with a long-term goal to identify effective biomarkers for diagnosis and therapeutic targets for personalized medicine.
In the past decade, we have mainly focused on: the identification of oncogenic drivers in lung cancer and the functional and mechanistic study of these important lung cancer related genes. In collaboration with Fudan University Shanghai Cancer Center, we have collected over 3000 human lung cancer specimens with comprehensive clinical information. Integrative genetic analyses of these lung cancer samples provides a spectrum of genomic DNA copy number variation, gene expression, gene mutation and gene fusions, which hopefully leads to the discovery to important oncogenic drivers in lung cancer. Among these candidates, LKB1 and the HPO pathway are proven to be important negative regulator of lung cancer malignant progression. We are actively investigating the potential function and mechanism of these molecules and seeking a way to treat these lung cancer with the inactivation of LKB1 or HPO pathway.
Currently, we are also very interested in lung cancer plasticity and drug resistance. Lung cancer is notorious its strong plasticity, which provides the major force for driving malignant progression, metastasis and more importantly, the therapeutic failure. EGFR-targeted therapy has been proved as a gigantic success in lung cancer clinic. However, it only lasts for half a year or so and all the patients inevitably relapse with progressive disease. Molecular reprogramming and phenotypic transition to small cell lung carcinoma have been reported responsible for cancer cells to escape drug treatment. Our recent findings of the transdifferentiation of lung adenocarcinoma to squamous cell carcinoma also suggest that the phenotypic transition represents a novel mechanism of lung cancer drug resistance. Understanding cancer plasticity during malignant progression and drug resistance hopefully provides a way for clinical management of this deadly disease. We take advantage of both genetically engineered mouse model (GEMM) and patient-derived xenograft (PDX) model to investigate the link between tumor plasticity and drug resistance. Hopefully, these works will provide a better understanding of lung cancerigenesis and improve current strategies for clinical lung cancer treatment.

Selected Publications

  1. Xiao Q, Jiang Y, Liu Q, Yue J, Liu C, Zhao X, Qiao Y, Ji H, Chen J, Ge G. Minor Type IV Collagen ¦Á5 Chain Promotes Cancer Progression through Discoidin Domain Receptor-1. PLoS Genet. 2015 May 19;11(5):e1005249.
  2. Li F, Han X, Li F, Wang R, Wang H, Gao Y, Wang X, Fang Z, Zhang W, Yao S, Tong X, Wang Y, Feng Y, Sun Y, Li Y, Wong KK, Zhai Q, Chen H*, Ji H*. LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response . Cancer Cell. 2015 27(5):698-711. Cover story. Research Watch in Cancer Discovery (DOI: 10.1158/2159-8290.CD-RW2015-089)
  3. Gao J, Wang Y, Cai M, Pan Y, Xu H, Jiang J, Ji H, Wang H. Mechanistic insights into EGFR membrane clustering revealed by super-resolution imaging. Nanoscale. 2015 7(6):2511-9.
  4. Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li J, Wang Z, Chen X, Zhang W, Yokoyama S, Wang C, Li L, Li L, Hou D, Dong L, Xu T, Hiroi T, Yang F, Ji H, Zhang J, Zen K, Zhang CY. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014 Oct;24(10):1164-80.
  5. Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, Li H, Ye T, Zhang Y, Luo X, Shao L, Sun Z, Cai D, Xu J, Lu Q, Deng Y, Shen L, Ji H, Sun Y, Chen H. Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. Onco Targets Ther. 2014 Aug 13;7:1423-37.
  6. Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, Fang Z, Tong X, Yao S, Li F, Feng Y, Sun Y, Hou Y, Yang Z, Guan K, Chen H, Zhang L*, Ji H*. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun. 2014 Aug 13;5:4629.
  7. Liu Z, Chen P, Gao H, Gu Y, Yang J, Peng H, Xu X, Wang H, Yang M, Liu X, Fan L, Chen S, Zhou J, Sun Y, Ruan K, Cheng S, Komatsu M, White E, Li L, Ji H, Finley D, Hu R*. Ubiquitylation of Autophagy Receptor Optineurin by HACE1 Activates Selective Autophagy for Tumor Suppression. Cancer Cell. 2014 Jul 14;26(1):106-120.
  8. Wang Y, Gao J, Guo X, Tong T, Shi X, Li L, Qi M, Wang Y, Cai M, Jiang J, Xu C*, Ji H*, Wang H*. Regulation of EGFR nanocluster formation by ionic protein-lipid interaction. Cell Res. 2014 Aug;24(8):959-76.
  9. Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, Pao W, Ji H*, Sun Y*, Chen H*. FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer. Clin Cancer Res. 2014 Aug 1;20(15):4107-14.
  10. Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, Reibel JB, Walton Z, Ji H, Watanabe H, Jänne PA, Castrillon DH, Rustgi AK, Bass AJ, Freeman GJ, Padera RF, Dranoff G, Hammerman PS, Kim CF, Wong KK. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014 May 12;25(5):590-604.
  11. Zong FY, Fu X, Wei WJ, Luo YG, Heiner M, Cao LJ, Fang Z, Fang R, Lu D, Ji H, Hui J. The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet. 2014 Apr 10;10(4):e1004289.
  12. Han X, Li F, Fang Z, Gao Y, Li F, Fang R, Yao S, Sun Y, Li L, Zhang W, Ma H, Xiao Q, Ge G, Fang J, Wang H, Zhang L, Wong KK, Chen H, Hou Y, Ji H*. Transdifferentiation of Lung Adenocarcinoma in mice with Lkb1 Deficiency to Squamous Cell Carcinoma. Nat Commun. 2014;5:3261.
  13. Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W, Wang X, Guo T, Li P, Zhao Y, Ji H*, Zhang L*, Zhou Z*. A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer. Cancer Cell. 2014 25,166-180.
  14. Fang R, Zheng C, Sun Y, Han X, Gao B, Li C, Liu H, Wong KK, Liu XY*, Chen H*, Ji H*. Brief Report: Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas. J Thorac Oncol, 2014 Feb;9(2):254-8.
  15. Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, Han X, Feng Y, Zheng C, Wang Z, Li F, Chen H, Zhou Z*, Zhang L*, Ji H*. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res, 2014 Mar;24(3):331-43.
  16. Huang W, She L, Chang XY, Yang RR, Wang L, Ji HB, Jiao JW, Poo MM. Protein kinase LKB1 regulates polarized dendrite formation of adult hippocampal newborn neurons. Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):469-74.
  17. Huang H, Li J, Hu L, Ge L, Ji H, Zhao Y, Zhang L. Bantam is essential for Drosophila intestinal stem cell proliferation in response to Hippo signaling. Dev Biol. 2014 Jan 15;385(2):211-9.
  18. Jin Y, Xu J, Yin MX, Lu Y, Hu L, Li P, Zhang P, Yuan Z, Ho MS, Ji H, Zhao Y, Zhang L. Brahma is essential for Drosophila intestinal stem cell proliferation and regulated by Hippo signaling. Elife. 2013 Oct 15;2:e00999.
  19. Jin Y, Li F, Zheng C, Wang Y, Fang Z, Guo C, Wang X, Liu H, Deng L, Li C, Wang H, Chen H, Feng Y*, Ji H*. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition. Int J Cancer. 2014 May 15;134(10):2294-304.
  20. Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med. 2013 Oct 11;5(10):91.
  21. Zeng L, Wan Y, Li D, Wu J, Shao M, Chen J, Hui L, Ji H, Zhu X. The m-subunit of murine translation initiation factor eIF3 maintains the integrity of the eIF3 complex and is required for embryonic development, homeostasis, and organ size control. J Biol Chem. 2013 Oct 18;288(42):30087-93.
  22. Guo T, Lu Y, Li P, Yin MX, Lv D, Zhang W, Wang H, Zhou Z, Ji H, Zhao Y, Zhang L. A novel partner of Scalloped regulates Hippo signaling via antagonizing Scalloped-Yorkie activity. Cell Res. 2013 Oct;23(10):1201-14.
  23. Wang Z, Sun Y, Gao B, Lu Y, Fang R, Gao Y, Xiao T, Liu XY, Pao W, Zhao Y*, Chen H*, Ji H*. Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome. Cancer Lett. 2014 Jan 1;342(1):36-42.
  24. Huang HL, Wang S, Yin MX, Dong L, Wang C, Wu W, Lu Y, Feng M, Dai C, Guo X, Li L, Zhao B, Zhou Z, Ji H, Jiang J, Zhao Y, Liu XY, Zhang L. Par-1 regulates tissue growth by influencing hippo phosphorylation status and hippo-salvador association. PLoS Biol. 2013 Aug;11(8):e1001620.
  25. Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, Hu H, Luo X, Ye T, Li H, Wang L, Chen H*, Ji H*. ANCCA Protein Expression is a Novel Independent Poor Prognostic Marker in Surgically Resected Lung Adenocarcinoma. Ann Surg Oncol. 2013 Dec;20 Suppl 3:S577-82.
  26. Han C, Huang Z, Zheng C, Wan L, Lai Y, Peng S, Ding K*, Ji H*, Zhang Y*. Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors. Eur J Med Chem. 2013 Aug;66:82-90.
  27. Han C, Huang Z, Zheng C, Wan L, Zhang L, Peng S, Ding K, Ji H*, Tian J*, Zhang Y*. Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer. J Med Chem. 2013 Jun 13;56(11):4738-48.
  28. Hu Y, He K, Wang D, Yuan X, Liu Y, Ji H, Song J. TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways. Carcinogenesis. 2013 Aug;34(8):1764-72.
  29. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, Shen L, Ji H#, Pao W, Sun Y#, Chen H#,*. (# equal contributation) RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer. J Clin Oncol. 2012, 30(35):4352-9.
  30. Feng Y, Wang Y, Wang Z, Fang Z, Li F, Gao Y, Liu H, Xiao T, Li F, Zhou Y, Zhai Q, Liu X, Sun Y, Bardeesy N, Wong KK, Chen H, Xiong ZQ, Ji H*. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. Cancer Res. 2012, 72(24):6502-11.
  31. Yang X, Zhao M, Xia M, Liu Y, Yan J, Ji H, Wang G. Selective requirement for Mediator MED23 in Ras-active lung cancer. Proc Natl Acad Sci U S A. 2012, 109(41):E2813-22.
  32. Huang H, Xiao T, He L, Ji H*, Liu XY*. Interferon-¦Â-armed oncolytic adenovirus induces both apoptosis and necroptosis in cancer cells. Acta Biochim Biophys Sin. 2012, 44(9):737-45.
  33. Jia P, Li F, Xia J, Chen H, Ji H, Pao W, Zhao Z*. Consensus rules in variant detection from next-generation sequencing data. PLoS One. 2012, 7(6):e38470.
  34. Wang Z, Feng Y, Bardessy N, Wong KK, Liu XY*, Ji H*.Temporal Dissection of K-rasG12D Mutant In Vitro and In Vivo Using a Regulatable K-rasG12D Mouse Allele. PLoS One. 2012, 7(5): e37308.
  35. Wang R, Pan Y, Li C, Hu H, Zhang Y, Li H, Luo X, Zhang J, Fang Z, Li Y, Shen L, Ji H, Garfield D, Sun Y, Chen H*. The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5¡¯ and 3¡¯ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers. Clin Cancer Res. 2012,18(17):4725-32.
  36. Yan Z, Shah PK, Amin SB, Samur MK, Huang N, Wang X, Misra V, Ji H, Gabuzda D, Li C. Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. Nucleic Acids Res. 2012, 40(17):e135.
  37. Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, Feng Y, Li L, Wang Y, Liu X, Chen H, Liu XY*, Ji H*. miR-143 regulates cancer glycolysis via targeting hexokinase 2. J Biol Chem. 2012, 287(27):23227¨C35.
  38. Cai M, Zhao W, Shang X, Jiang J, Ji H, Tang Z, Wang H. Direct Evidence of Lipid Rafts by in situ Atomic Force Microscopy. Small. 2012, 8(8):1243-50.
  39. Li F, Feng Y, Fang R, Fang Z, Xia J, Han X, Chen H*, Liu H*, Ji H*. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res. 2012, 22(5):928-31.
  40. N. Girard, C.S. Sima, D.M. Jackman, L.V. Sequist, H. Chen, J.C-H. Yang, H. Ji, B. Waltman, R. Rosell, M. Taron, M.F. Zakowski, M. Ladanyi, G. Riely, W. Pao. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. EUR RESPIR J. 2012, 39(2): 366-372.
  41. Xao T, Bao L, Ji H*. Finding biomarkers for non-small cell lung cancer diagnosis and prognosis. Front. Biol. 2012, 7(1): 14¨C23.
  42. Bergethon K, Shaw AT, Ignatius Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. J Clin Oncol. 2012, 30(8):863-70.
  43. Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, Shen L, Ji H*, Chen H*. Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains. J Thorac Oncol. 2012, 7(1):85-9.
  44. Fang Z, Tian W*, Ji H*. A network-based gene-weighting approach for pathway analysis. Cell Res. 2012, 22(3):565-80.
  45. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H, Ji H*. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East asian never smokers. PLoS One. 2011, 6(11):e28204.
  46. Zhao H, Zhu L, Jin Y, Ji H, Yan X, Zhu X. miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells. Acta Biochim Biophys Sin. 2011, 44(2):177-82.
  47. Saab ST, Lovly C, Hollis CJ, Ashwini Y, Ji H, Pao W, Gonzalez A. Immunohistochemical Analysis of ALK Fusion-Positive Lung Cancers: Correlation with FISH,Molecular Findings and Morphology. LABORATORY INVESTIGATION. 2011, 91423A-423A.
  48. Li C, Sun Y, Fang Z, Han X, Fang R, Zhang Y, Pan Y, Zhang W, Ren Y, Ji H*, Chen H*. Comprehensive Analysis of Epidermal Growth Factor Receptor (EGFR) Gene Status in Lung Adenocarcinoma from Chinese Patients. J Thorac Oncol. 2011, 6:1016-21.
  49. Cao Y, Li H, Liu H, Zhang M, Hua Z, Ji H, Liu X. LKB1 regulates TCR-mediated PLC¦Ã1 activation and thymocyte positive selection. EMBO J. 2011, 30:2083-93.
  50. Gao Y, Ge G*, Ji H*. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell. 2011, 2(2):99-107.
  51. Zheng C, Sun Y, Ye X, Chen HQ*, Ji HB*. Establishment and characterization of primary Chinese lung cancer cell lines. Acta Pharmacol Sin. 2011, 32, 385-92.
  52. Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, Fang Z, Wu J, Han X, Zhang J, Sun Y, Wu G, Padera R, Chen H, Wong KK, Ge G*, Ji H*. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A. 2010, 107(44):18892-7.
  53. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W#, Chen H#, Ji H#.(# equal contribution) Lung adenocarcinoma from East asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010, 28, 4616-20.
  54. Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Liu XY, Pao W, Chen H*, Ji H*. Spectrum of LKB1, EGFR and KRAS mutations in Chinese lung adenocarcinomas. J Thorac Oncol. 2010, 5,1130-5.
  55. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, Garc¨ªa-Echeverr¨ªa C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 2010,17,547-59.
  56. Sun Y, Fang R, Gao B, Han X, Zhang J, Pao W, Chen H, Ji H*. Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin. 2010, 31,647-8.
  57. Ji H*. Mechanistic insights into acquired drug resistance in EGFR mutation targeted lung cancer therapy. Can Sci. 2010,101(9):1933-8.
  58. Wang L, Xiong Y, Sun Y, Fang Z, Li L, Ji H*, Shi T*. HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res. 2010, 38,D665-9.
  59. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, Jenkins KM, Beaulieu KA, Mouded M, Frank SJ, Wong KK, Shapiro SD. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010, 16(2):219-23.
  60. Cao Y, Li H, Liu H, Zheng C, Ji H, Liu X. The serine/threonine kinase LKB1 controls thymocyte survival through regulation of AMPK activation and Bcl-XL expression. Cell Res. 2010, 20(1):99-108.
  61. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009, 106(2):474-9.
  62. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, Padera RF, Kubo S, Takahashi M, Tenen DG, Meyerson M, Wong KK, Shapiro GI. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008, 68(14):5827-38.
  63. Zhou X, Bao H, Al-Hashem R, Ji H, Albert M, Wong KK, Sun Y. Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. Comp Med. 2008, 58(3):276-81.
  64. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007, 448(7155):807-10.
  65. Li D#, Shimamura T#, Ji H# (#equal contribution), Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Janne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 2007, 12(1):81-93.
  66. Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M. Allele-Dependent Variation in the Relative Cellular Potency of Distinct EGFR Inhibitors. Cancer Biol Ther. 2007, 6(5):661-7.
  67. Ji H, Wang Z, Perera A.S., Li D, Liang M-C, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac L.R., Padera R., Bronson R.T., Thomas R. K., Garraway L.A., Janne P.A., Johnson B.E., Chin L., and Wong KK. Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models. Cancer Res. 2007, 67(10):4933-9.
  68. Li D#, Ji H# (#equal contribution)£¬Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee WK, Old LJ, Demetri GD, Wong KK. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest. 2007, 117(2):346-52.
  69. Ji H, Sharpless NE, Wong KK. EGFR targeted therapy: view from biological standpoint. Cell Cycle. 2006, 5(18):2072-6.
  70. Shimamura T#, Ji H# (#equal contribution), Minami Y, Thomas R.K., Lowell A.M., Shah K., Greulich H, Glatt K.A., Meyerson M.L., Shapiro G.I. and Wong KK. Non-small cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific EGFR and ERBB2 inhibitor HKI-272. Cancer Res. 2006, 66(13):6487-91.
  71. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac L.R, Padera R, Bronson R. T, Kim W, Janne P.A, Shapiro G.I, Tenen D, Johnson B.E, Weissleder R, Sharpless N.E, Wong KK. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR targeted therapies. Cancer Cell. 2006, 9(6):485-95.
  72. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung B.L, McNamara K, Xia H, Glatt K.A, Thomas R.K, Sasaki H, Horner J.W, Mitchell A, Sun Y, Al-Hashem R, Bronson R.T, Rabindran S.K, Discafani C.M, Maher E, Shapiro G.I, Meyerson M, Wong KK. Epidermal Growth Factor Receptor Variant III Mutations in Lung Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors. Proc Natl Acad Sci USA. 2006, 103(20):7817-22.
  73. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, Tonon G, McNamara K, Marconcini LA, Hezel A, El-Bardeesy N, Bronson RT, Sugarbaker D, Shapiro SD, Wong KK. K-Ras Activation Generates An Inflammatory Response in Lung Tumors. Oncogene. 2006, 25(14):2105-12.
  74. Wong KK, Maser RS, Sahin E, Bailey ST, Xia H, Ji H, McNamara K, Naylor M, Bronson RT, Ghosh S, Welsh R, Depinho RA. Diminished lifespan and acute stress-induced death in DNA-PKcs-deficient mice with limiting telomeres. Oncogene. 2007, 26(20):2815-21.
  75. Abad¨ªa-Molina AC#, Ji HB# (#equal contribution), Faubion WA, Julien A, Latchman Y, Yagita H, Sharpe A, Bhan AK, Terhorst C. CD48 controls T-cell and antigen-presenting cell functions in experimental colitis. Gastroenterology. 2006, 130(2):424-34.
  76. Bass¨¨res DS, Levantini E, Ji H, Monti S, Elf S, Dayaram T, Fenyus M, Kocher O, Golub T, Wong KK, Halmos B, Tenen DG. Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice. Mol Cell Biol. 2006, 26(3):1109-23.
  77. Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, Laroux FS, Caton A, Terhorst C. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol. 2004, 172(10): 5823-7.
  78. Tonon G, Wong KK, Maulik G, Brennan G, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, DePinho RA. Common High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA. 2005, 102(27):9625-30.
  79. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B.¡¡An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005, 65(16):7096-101.
  80. Tonon G, Brennan C, Protopopov A, Maulik G, Feng B, Zhang Y, Khatry DB, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Wong KK, Depinho RA. Common and contrasting genomic profiles among the major human lung cancer subtypes. Cold Spring Harb Symp Quant Biol. 2005, 70:11-24.
  81. Okamoto S, Ji H, Howie D, Clarke K, Gullo C, Manning S, Coyle AJ, Terhorst C. Expression of the SH2D1A gene is regulated by a combination of transcriptional and post-transcriptional mechanisms. Eur J Immunol. 2004, 34(11):3176-86.
  82. Faubion WA, De Jong YP, Molina AA, Ji H, Clarke K, Wang B, Mizoguchi E, Simpson SJ, Bhan AK, Terhorst C. Colitis is associated with thymic destruction attenuating CD4+25+ regulatory T cells in the periphery. Gastroenterology. 2004, 126(7):1759-70.
  83. Schmidt-Supprian M, Tian J, Ji H, Terhorst C, Bhan AK, Grant EP, Pasparakis M, Casola S, Coyle AJ, Rajewsky K. I kappa B kinase 2 deficiency in T cells leads to defects in priming, B cell help, germinal center reactions, and homeostatic expansion. J Immunol. 2004, 173(3):1612-9.
  84. Ji HB, Gupta A, Okamoto S, Blum MD, Tan L, Goldring MB, Lacy E, Roy AL, Terhorst C. T cell-specific expression of the murine CD3delta promoter. J Biol Chem. 2002, 277(49): 47898-906.
  85. Xie L, Wang BZ, Hu RG, Ji HB, Zhang L, Liu WY. Structural and functional studies of cinnamomin, a new type II ribosome-inactivating protein isolated from the seeds of the camphor tree. Eur J Biochem. 2001, 268(22): 5723-33.
  86. Tang W, Huo H, Zhu J, Ji HB, Zou W, Xu L, Sun L, Zheng Z, Theze J, Liu X. Critical sites for the interaction between Il-2Rgamma and JAK3 and the following signaling. Biochem Biophys Res Commun. 2001, 283(3):598-605.
  87. Zhai QW, Ji HB, Yan MD, Zheng ZC, Sun LY, Liu XY. Investigating the function of Akt by tet-off inducible expression system. Chinese Science Bulletin. 2001, 46(3):222-225.
  88. Ji H, Zhai Q, Zhu J, Yan M, Sun L, Liu X, Zheng Z. A novel protein MAJN binds to Jak3 and inhibits apoptosis induced by IL-2 deprival. Biochem Biophys Res Commun. 2000, 270(1):267-71.
  89. Ji HB, Zhai QW, Liu XY, Zheng ZC. Transcription Regulation of bcl-2 Gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao. 2000, 32(2):95-99.
  90. Ji HB, Zhai QW, Zhu JF, Sun LY, Liu XY, Zheng ZC. Interaction between Jak3 and Nucleosome Assembly Protein 1. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao. 2000, 32(1):4-8.
  91. Zhai Q, Ji H, Zheng Z, Yu Xiang, Sun L and Liu X. Copper induces apoptosis in BA/F3beta cells: Bax, reactive oxygen species and NfkappaB are involved. Journal of Cellular Physiology, 2000, 184(2):161-170.
  92. Zhai QW, Ji HB, Zheng ZC, Sun LY, Liu XY. A Novel Type of Apoptosis Induced by Cadmium in BA/F3beta Cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao. 2000, 32(1):77-80.
  93. Zhu JF, Ji HB, Tang W, Liu XY, Zheng ZC. Isolation and Characterzation of p160.2, a Signal Transducing Protein Downstream of Jak3. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao. 1999, 31(3):293-297.
  94. Zhu J, Tang W, Ji H, Zheng Z and Liu X. Study on the interaction between Jak3 and Il-2R gamma using the yeast two-hybrid system. Chinese Science Bulletin, 1999, 14(18):1664-1668.
  95. Zhu J, Ji H, Lu L, Guo L. Zheng Z, Liu X. The positive and negative control actions of PTPase on Il-2 signaling. Science in China. 1999, 42(6):614-620.
  96. Lu J, Ji H, Zheng Z, Liu X. Signal for IL-2 internalization located in the endocellular domain of IL-2R g subunit only. Chinese Science Bulletin. 1998, 43(16):1390-1395.
  97. Zhu J, Lu L, Ji H, Zheng Z, Theze J and Liu X. JAK3 mediates c-myc gene expression induced by interleukin-2. Chinese Science Bulletin, 1998, 43(4):308-311.

Education Background & Academic Experience
2007- present: Principal Investigator, Professor, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China.
2004-2007: Research fellow/Instructor, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, U.S.A.
2000-2004: Research associate, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, U.S.A.
1995-2000: Ph.D. in Biochemistry and Molecular Biology, Shanghai Institute of Biochemistry, Chinese Academy of Sciences, Shanghai, China.
1991-1995: B.S. in Biochemistry, Jilin University, Changchun, China.


Copyright © 2017-2020¡¡Shanghai Institute of Biochemistry and Cell Biology, CAS.¡¡All rights reserved